Original article: Prognostic factors in hormone-resistant progressing cancer of the prostate (Q45105155)

reason for preferred rank

9 December 2017

title

Original article: Prognostic factors in hormone-resistant progressing cancer of the prostate (English)

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

16 October 2022

Prognostic factors in hormone-resistant progressing cancer of the prostate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1616889

16 October 2022

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

16 October 2022

1

S D Fosså

1 reference

9 December 2017

D. P. Dearnaley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1616889

16 October 2022

M. Law

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1616889

16 October 2022

J. Gad

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1616889

16 October 2022

D. W. Newling

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1616889

16 October 2022

K. Tveter

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1616889

16 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1616889

16 October 2022

publication date

1 May 1992

1 reference

full work available at URL

9 December 2017

http://annonc.oxfordjournals.org/cgi/content/abstract/3/5/361

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1616889

https://api.elsevier.com/content/article/PII:S0923753419652294?httpAccept=text/xml

16 October 2022

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

https://api.elsevier.com/content/article/PII:S0923753419652294?httpAccept=text/plain

16 October 2022

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

http://academic.oup.com/annonc/article-pdf/3/5/361/600177/3-5-361.pdf

16 October 2022

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

16 October 2022

1 reference

9 December 2017

volume

3

1 reference

9 December 2017

issue

5

1 reference

9 December 2017

page(s)

361-366

1 reference

Reporting results of cancer treatment

9 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

16 October 2022

2

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

Comparison of the effects of high dose Estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: an interim analysis of EORTC-GU Group stud

16 October 2022

3

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

16 October 2022

5

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

Treatment of Metastatic Endocrine-Unresponsive Carcinoma of the Prostate Gland With Multiagent Chemotherapy: indicators of Response to Therapy2

16 October 2022

7

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate

16 October 2022

8

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome

16 October 2022

9

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment

16 October 2022

10

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials.

16 October 2022

11

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06

16 October 2022

12

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease

16 October 2022

15

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058207

16 October 2022

Identifiers

1 reference

9 December 2017

1 reference